Shandong Wit Dyne Health Co (000915) Fair Value & Analysis

Healthcare · CN · Market cap 6.5B CNY

Analysis

Shandong Wit Dyne Health Co (000915) currently trades at ¥26.91, while our model-based Fair Value estimate is ¥50.24 — implying the stock looks roughly 86.7% undervalued today. We read business quality at 80/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Shandong Wit Dyne Health Co.,Ltd. engages in the pharmaceutical business in China. Its medical products include azithromycin granules, licorice zinc granules, compound calcium carbonate, vitamin AD drops, epalrestat tablets, valsartan hydrochlorothiazide gel, roxithromycin, rosiglitazone tartrate tablets, and glimepiride tablets. The company also provides dextran iron granules, oral rehydration salt powder, montmorillonite powder, azithromycin granules, rifaximin dry suspension, and succinate capsules. In addition, it offers information products, such as DLP splicing display units, LCD splicing display units, image splicing processors, communication products, and industrial automation control products; and crystal products. Shandong Wit Dyne Health Co.,Ltd. was founded in 1993 and is based in Jinan, China

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.